Repare Therapeutics Inc. (NASDAQ:RPTX) Receives $30.80 Average PT From Analysts
Repare Therapeutics Inc. (NASDAQ:RPTX) Receives $30.80 Average PT From Analysts
Shares of Repare Therapeutics Inc. (NASDAQ:RPTX – Get Rating) have earned a consensus rating of "Moderate Buy" from the six ratings firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $30.80.
Marketbeat.com报道,Repare Therapeutics Inc.(纳斯达克股票代码:RPTX — Get Rating)的股票已从目前报道该公司的六家评级公司获得了 “适度买入” 的共识评级。一位分析师对该股进行了持有评级,五位分析师对该公司给予了买入评级。去年更新该股报道的分析师的12个月平均目标股价为30.80美元。
A number of research analysts recently weighed in on the stock. HC Wainwright dropped their price objective on shares of Repare Therapeutics from $38.00 to $25.00 and set a "buy" rating for the company in a report on Thursday, November 17th. Capital One Financial assumed coverage on shares of Repare Therapeutics in a report on Friday. They issued an "overweight" rating and a $28.00 price objective for the company.
一些研究分析师最近对该股进行了权衡。HC Wainwright在11月17日星期四的一份报告中将Repare Therapeutics股票的目标价格从38.00美元下调至25.00美元,并为该公司设定了 “买入” 评级。Capital One Financial在周五的一份报告中假设对Repare Therapeutics的他们为该公司发布了 “增持” 评级和28.00美元的目标价格。
Repare Therapeutics Price Performance
Repare 疗法的价格表现
Shares of RPTX opened at $14.25 on Friday. Repare Therapeutics has a 1-year low of $8.06 and a 1-year high of $19.24. The stock has a market cap of $597.96 million, a PE ratio of -19.52 and a beta of 0.11. The firm has a 50-day simple moving average of $15.53 and a two-hundred day simple moving average of $13.95.
周五,RPTX的股价开盘价为14.25美元。Repare Therapeutics创下1年低点8.06美元,1年高点为19.24美元。该股的市值为5.9796亿美元,市盈率为-19.52,beta值为0.11。该公司的50天简单移动平均线为15.53美元,两百天简单移动平均线为13.95美元。
Insider Activity at Repare Therapeutics
Repare Thareutics 的内部活动
In related news, Director Davis Jerel sold 250,000 shares of Repare Therapeutics stock in a transaction that occurred on Friday, December 9th. The shares were sold at an average price of $16.00, for a total value of $4,000,000.00. Following the completion of the transaction, the director now owns 2,094,451 shares in the company, valued at $33,511,216. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 33.60% of the company's stock.
在相关新闻中,董事戴维斯·杰雷尔在12月9日星期五进行的一笔交易中出售了25万股Repare Therapeutics股票。这些股票的平均价格为16.00美元,总价值为4,000,000.00美元。交易完成后,该董事现在拥有该公司的2,094,451股股票,价值33,511,216美元。此次出售是在向美国证券交易委员会提交的法律文件中披露的,该文件可以通过以下方式获得 这个超链接。公司内部人士拥有该公司33.60%的股份。
Institutional Inflows and Outflows
机构流入和流出
A number of institutional investors have recently added to or reduced their stakes in RPTX. Bartlett & Co. LLC purchased a new position in Repare Therapeutics in the second quarter worth approximately $28,000. UBS Group AG lifted its position in shares of Repare Therapeutics by 26.3% during the 3rd quarter. UBS Group AG now owns 3,551 shares of the company's stock worth $43,000 after buying an additional 739 shares during the last quarter. Bpifrance SA purchased a new stake in shares of Repare Therapeutics during the 2nd quarter worth approximately $113,000. Tower Research Capital LLC TRC purchased a new stake in shares of Repare Therapeutics during the 3rd quarter worth approximately $113,000. Finally, Fox Run Management L.L.C. purchased a new stake in shares of Repare Therapeutics during the 3rd quarter worth approximately $143,000. Hedge funds and other institutional investors own 78.19% of the company's stock.
许多机构投资者最近增加了或减少了在RPTX的股份。Bartlett & Co.LLC在第二季度收购了Repare Therapeutics的新头寸,价值约28,000美元。瑞银集团股份公司在第三季度将其在Repare Therapeutics的股票头寸上调了26.3%。瑞银集团股份公司在上个季度又购买了739股股票后,现在拥有该公司3,551股股票,价值43,000美元。Bpifrance SA在第二季度购买了Repare Therapeutics的新股份,价值约11.3万美元。Tower Research Capital LLC TRC在第三季度购买了Repare Therapeutics的新股份,价值约11.3万美元。最后,Fox Run Management L.L.C. 在第三季度购买了Repare Therapeutics的新股份,价值约14.3万美元。对冲基金和其他机构投资者拥有该公司78.19%的股票。
Repare Therapeutics Company Profile
Repare Therapeutics
(Get Rating)
(获取评分)
Repare Therapeutics Inc, a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair.
Repare Therapeutics Inc是一家临床阶段的精准肿瘤学公司,通过在加拿大和美国使用其合成致死性方法发现和开发治疗药物。该公司使用其专有的、全基因组且支持CRISPR的平台SnipRX来系统地发现和开发高度靶向的癌症疗法,这些疗法侧重于基因组不稳定性,包括DNA损伤修复。
Read More
阅读更多
- Get a free copy of the StockNews.com research report on Repare Therapeutics (RPTX)
- Will LI Auto Be the Least Hated Chinese EV Stock in 2023?
- Which Streaming Service Stock is Best in 2023?
- Here's Why Snap Stock Can Double in 2023
- MarketBeat: Week in Review 01/02-01/06
- Why is the CrowdStrike Stock Price Struggling?
- 免费获取 StockNews.com 关于 Repare Therapeutics (RPTX) 的研究报告的副本
- LI Auto 会成为 2023 年最不讨厌的中国电动汽车股票吗?
- 2023 年哪只流媒体服务股票最好?
- 这就是为什么 Snap 股票可以在 2023 年翻一番的原因
- MarketBeat:本周回顾 01/02-01/06
- 为什么 CrowdStrike 的股价陷入困境?
Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每天接收 Repare Therapeutics 的新闻和评级 -在下面输入您的电子邮件地址,即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Repare Therapeutics及相关公司的最新新闻和分析师评级的简明每日摘要。